Brief Introduction {#s1}
==================

By virtue of being a small, amphiphilic, indoleamine molecule, melatonin (5-methoxy-N-acetyl tryptamine) is synthesized *de novo* from serotonin (5-hydroxy-tryptamine), a highly dispersed biologically active molecule in its own right. Historically, melatonin has been considered an endocrine hormone released from the epithalamic pineal gland, which then acts on specific G-protein-coupled melatonin receptors in target tissues of both adults and the fetus ([@B1], [@B2]). More recently, melatonin has been reported to be synthesized in small amounts by a wide variety of animal cells and tissues as well as diverse organisms, including all kingdoms of living organisms \[cf. ([@B3], [@B4])\], where it presumably has local paracrine and autocrine actions, some of which are probably independent of specific melatonin receptors ([@B5]). Indeed, melatonin has been reported to interact with a great many cellular proteins, including enzymes, channels, transporters, signaling molecules, etc \[for a recent comprehensive review, see ([@B6])\]. Thus, melatonin is perhaps best defined as both a pineal hormone and a bioactive amine with cellular targets near its site of synthesis in some tissues.

While such generalizations permit the inclusion of many effects, it doesn\'t remove a number of challenges for the interpretation of the research data involving melatonin. For example, with regard to targets, the reported affinities of the two known human melatonin receptors (in both cell expression systems and *ex vivo*) are in the nanomolar range \[cf. ([@B7])\], whereas many if not most experimental protocols have employed very pharmacological concentrations to achieve significant effects. Another point to consider is that although plasma melatonin levels are physiologically elevated for many hours at nighttime, protocols often expose tissues or cells to only very short melatonin treatments, which may be physiologically irrelevant. A common response to these concerns is that local concentrations may be quite high and/or constant---especially if there is local constitutive melatonin synthesis. Recent studies suggest that melatonin synthesis by mitochondria may be important for subcellular physiological processes ([@B8]). However, there is little experimental evidence that disruption of such local melatonin production has meaningful cellular consequences \[in contrast to the removal of plasma melatonin via extirpation of the pineal gland, which has numerous effects on the reproductive axis of laboratory animals - cf. ([@B9])\].

The human being is exposed to varying levels of melatonin from conception to death. Much like the hormones thyroxine, insulin or cortisol, the molecule melatonin has a variety of diverse roles to play as a function of developmental life stage (embryo, neonate, adolescent, or adult). It seems likely that many of these actions of melatonin could be permissive or synergistic (like the aforementioned hormones), but there is remarkably scant research into this distinct possibility. A significant step in this direction are the findings of circadian clock gene regulation by melatonin in several tissues of the reproductive axis in both the embryo and adults.

Melatonin has often been described as a chemical output signal of the central circadian oscillator (the hypothalamic suprachiasmatic nuclei, SCN). The clearest support for this statement is the abolition of plasma melatonin rhythmicity following disruption of the neural connectivity between the SCN and the pineal gland. As mentioned earlier, the nocturnal melatonin signal duration is of major importance for physiological seasonality, however, the circadian phasing of the melatonin signal has important ramifications for general circadian functions, including body temperature, endocrine rhythms, and sleep ([@B10]). This is in part due to fact that melatonin receptors are expressed in the SCN and can mediate phase-shifting feedback effects of melatonin. Hence, in clinical studies of melatonin actions on the reproductive (or any) system, it is imperative to keep issues such as the timing of melatonin administration (day vs. night) and the duration of the plasma melatonin levels following exogenous melatonin administration in mind. Unfortunately, these considerations are too often overlooked in clinical trials involving melatonin treatments.

Especially in the area of reproductive biology, it is clear that the physiology of animal models is often not comparable to the human state, most especially with regard to ovulatory cycles and the regulation of pregnancy \[cf. ([@B11])\]. Hence, promising results from melatonin experiments in other species need to be confirmed in clinical trials before one can draw any conclusions of relevance to reproductive medicine. The most obvious historical case in point is the controversy in the late decades of the twentieth century regarding melatonin as an "anti-gonadotrophic" or a "pro-gonadotrophic" hormone (in the human it is physiologically neither, although at high doses there may be some inhibitory effect on ovulation---see more below).

Human reproduction is a challenging object of study for obvious reasons, e.g., population heterogeneity, ethical limits when experimenting with humans, high research costs and appropriate technologies, etc. The quality of clinical data---its statistical power, reproducibility, appropriateness of controls, treatment variations, and so on---make the attainment of firm conclusions thus far about melatonin\'s normal physiological role in human reproduction difficult. Similarly, validation of proposed pharmacological uses for melatonin or analogs in the treatment of puberty, infertility, menopause, etc has not yet been achieved due to limited published scientific literature. The goal of this chapter is stimulate future research into the relationship of melatonin to human reproductive function in anticipation of generating novel diagnostic and therapeutic tools to improve human health and fertility.

Melatonin and Puberty {#s2}
=====================

Clinical reports from "pre-melatonin" days (i.e., prior to Aaron Lerner\'s discovery of the hormone in 1958) identified a potential link between human puberty and pineal tumors. For example, early in the twentieth century Marburg \[see his ([@B12]) review\]---based on reported clinical findings of pineal tumors in children---developed the hypothesis that secretions of the pineal inhibit human reproductive activity. Indeed some clinicians of that generation used pineal extracts to treat precocious puberty ([@B13]).

Following the seminal studies of Wurtman et al. ([@B14])---who demonstrated antigonadal effects of melatonin in female rats---the investigation of melatonin\'s impact on mammalian reproduction rapidly expanded \[cf. ([@B15])\]. However, with regard to human puberty and its regulation by melatonin, conflicting reports appeared in the later quarter of the twentieth century. Whereas, some groups found higher plasma melatonin levels associating with prepubertal and delayed pubertal conditions ([@B16], [@B17]) and inversely lower levels of melatonin after puberty or in cases of precocious puberty ([@B18]--[@B20]), numerous other groups found no significant differences between normal and disordered puberty ([@B21]--[@B24]). These discrepancies have led to skepticism among twenty-first century clinicians regarding the importance of melatonin in normal pubertal development. In both young males and females, the puberty-related decline of high childhood melatonin levels has been correlated more to advancing Tanner stages than to chronological age ([@B25]), but no clear causative basis for this relationship has been established for humans.

In view of the circadian secretion of melatonin and the circadian nature of pituitary hormone levels during puberty and in adults, it has long been suggested that melatonin regulates human reproductive cycles. The pulsatile release of GnRH and hence gonadotropin pulse frequency is highest during the night during puberty ([@B26]) and the monthly surge of LH and FSH secretion at ovulation also occurs mainly during the latter hours of the dark phase ([@B27], [@B28]). To what extent the temporal coincidence of hypothalamic secretions with melatonin release simply reflects coordinated downstream activation of neural pathways under control of the central circadian oscillator in the SCN as opposed to explicit regulation of the neuroendocrine axis by melatonin remains unclear---most likely both pathways play some role.

Melatonin and the Female Reproductive Cycle {#s3}
===========================================

Melatonin receptors have been demonstrated in a variety of cell types in the female reproductive tract uterus. As shown in [Table 1](#T1){ref-type="table"} the majority of studies demonstrate dual expression of both MT1 and MT2 receptors. Hence, one should consider all of these cells to be potential targets for melatonin action.

###### 

Melatonin binding sites in the human female reproductive system.

  ----------------------------------------------------------------------------------------------------------
  **Organ**   **Cells**              **Receptor type**   **Response**                    **References**
  ----------- ---------------------- ------------------- ------------------------------- -------------------
  Ovary       Granulosa/luteal       nd                  ↑ P4                            ([@B29]--[@B31])

                                     MT1, MT2            ↓ P4                            ([@B32], [@B33])

                                     nd                  ↓ BMP6 signaling                ([@B34])

                                     nd                  ↓ oxid. Stress                  ([@B31])

  Uterus      Myometrium             MT1, MT2            ↑ contractility                 ([@B35], [@B36])

                                                                                         ([@B37])

  Breast      Glandular epithelium   MT1                 ↓ERα transcriptional activity   cf. ([@B38])

  Placenta    Choriocarcinoma        MT1, MT2            ↓hCG secretion                  ([@B39])

              Trophoblast            MT1, MT2            ↓Inflammation, autophagy        ([@B40], [@B41])\
                                                                                         ([@B42], [@B43])
  ----------------------------------------------------------------------------------------------------------

Some 30 years ago, Brzezinski et al. demonstrated that human preovulatory follicular fluid contained melatonin at levels higher than plasma melatonin levels ([@B44]). This was subsequently confirmed and later shown to vary inversely with day length and concomitantly with follicular progesterone (P4) levels ([@B45], [@B46]), suggesting preferential uptake of circulating melatonin by the ovary. Nakamura et al. ([@B47]) subsequently found that larger preovulatory follicles had higher melatonin levels than smaller immature follicles. Later observations that increasing oral doses of melatonin results in significantly elevated melatonin concentrations in follicular fluid of women volunteers ([@B48]) also support this view. Several reports followed in which melatonin was shown to modulate progesterone production by cultured human granulosa/luteal cells ([@B29], [@B49], [@B50]). More recently, the effects of melatonin on cultured human granulosa/luteal cells has been extended to include synergism with hCG---albeit at very high melatonin concentrations ([@B51]).

Interestingly, when combined with progesterone, melatonin at high doses is able to suppress human ovulation ([@B52]). As will be discussed later, rising progesterone levels during human pregnancy (when ovulation is strongly suppressed) are accompanied by rising plasma melatonin levels. It could be insightful to assess the effects of progesterone on melatonin receptor expression in the human ovary and other reproductive tissues.

Among 61 women undergoing assisted reproductive therapy (ART) treatment cycles it was reported that a positive correlation exists between follicular melatonin levels and markers of ovarian reserve, e.g., anti-Muellerian hormone and baseline FSH levels ([@B53]). These authors also found a similar correlation between follicular fluid melatonin levels and *in vitro* fertilization (IVF) outcomes and oocyte quality. Similarly, Zheng et al. ([@B54]) found a significant positive correlation between follicular fluid melatonin concentrations and antral follicle count in women undergoing *in vitro* fertilization---also consistent with a supportive or protective action of melatonin on ovarian cycle progression.

These results have motivated a number of studies into the potential benefit of pharmacological melatonin supplementation in the treatment of infertility \[cf. ([@B55]) for review\]. Although the etiology of infertility is complex and not fully clarified, a recurring aspect appears to be excessive production of reactive oxygen species in the follicular fluid ([@B56]). In an oft-cited study by Tamura et al. ([@B57]), it was reported that when patients were given 3 mg of melatonin orally in the evening from the fifth day of the previous menstrual cycle until the day of oocyte retrieval, intra-follicular concentrations of melatonin rose 4-fold. Markers of intra-follicular oxidative damage were decreased after melatonin treatment compared to those in the prior cycle, suggesting that melatonin treatment reduces intra-follicular oxidative stress. These investigators then assessed the clinical outcomes of 115 patients who failed to become pregnant in the previous IVF-ET cycle with a low fertilization rate (\< 50%). In the 56 patients treated with melatonin, the fertilization rate (50.0 ± 38.0%) was markedly improved compared with the previous IVF-ET cycle (20.2 ± 19.0%), and 11 of 56 patients (19.6%) achieved pregnancy. In contrast, in the 59 control patients, the fertilization rate (22.8 ± 19.0 vs. 20.9 ± 16.5%) was not significantly changed, and only 6 of 59 patients (10.2%) achieved pregnancy. These intriguing findings are consistent with the view that pharmacological melatonin administration increases intra-follicular melatonin concentrations, reduces intra-follicular oxidative damage and may have a beneficial effect on fertilization and pregnancy rates during ART. In a recent report, similar benefits were found in 40 women with idiopathic infertility who were administered pharmacological melatonin and who subsequently showed improved intrafollicular oxidative capacity and oocyte quality in IVF protocols ([@B58]).

These data point to a potential benefit of melatonin in the process of oogenesis. In this regard, the high levels of melatonin required for effects seem consistent with high follicular fluid concentrations of melatonin. Some investigators have also proposed that follicular granulosa cells have the capability for local melatonin synthesis ([@B59], [@B60]), which if confirmed would add new insight into melatonin\'s role as a paracrine modulator in the reproductive system of humans.

Many female reproductive hormones undergo 24-h rhythms under both standard sleep-wake cycles and under constant routine conditions, indicating that they are under endogenous circadian control ([@B61], [@B62]). Interestingly, these rhythms are robust in the early follicular phase but not in the luteal phase of the menstrual cycle, which is largely under the control of high luteal progesterone secretions. Perturbations of the human circadian system (e.g., from shift work) are known to disrupt reproductive cycles \[cf. ([@B63]) for review\]. However, data are lacking on the potential role of melatonin to the etiology of these disruptions, despite initial early findings in one small study ([@B64]) that demonstrated a high incidence of irregular menstrual cycles in night workers whose melatonin levels were significantly suppressed.

Melatonin and Pregnancy {#s4}
=======================

Following earlier research on maternal transfer of melatonin to the fetus and neonatal development of pineal melatonin rhythmicity in the 1980s and 1990s ([@B65]--[@B67]), a period of relative quiescence welcomed the transition to a new millennium. However, a growing number of studies in the past decade have focused on the action of melatonin on the placenta and fetal development as well as circadian roles for melatonin before and after parturition.

It is now relatively well-established that a prime entrainment signal from the maternal circulation to fetus is melatonin ([@B68]), which crosses the placenta ([@B69]), and can bind to melatonin receptors in numerous fetal tissues ([@B70]).

Melatonin receptor (MT1 and MT2) transcripts and proteins have also been detected in human placentae ([@B39]--[@B41]) and subsequently shown to be expressed throughout pregnancy, albeit with declining levels after the first trimester ([@B71]). In addition, mRNA and protein expression of the melatonin-synthesizing enzymes, AANAT and HIOMT, have also been reported ([@B40], [@B41]), leading to the view that in addition to the rising plasma melatonin levels during pregnancy ([@B72]), local production of melatonin may serve an additional paracrine role. One target may be the placental trophoblast cells, which secrete the "pregnancy hormone" human chorionic gonadotropin (hCG). In two separate laboratories, it was found that high micromolar to millimolar concentrations of melatonin *in vitro* significantly elevated hCG release by human trophoblast cells ([@B40], [@B71]). More recently, the latter group also reported that melatonin at these high levels protects trophoblast cells *in vitro* against hypoxia/reoxygenation--induced inflammation and autophagy ([@B42]).

Another potential target for melatonin may be the vascularization of the placenta in early pregnancy through remodeling of the maternal uterine spiral arteries, a process that appears to be defective in preeclampsia---a leading cause of maternal mortality, especially in developing countries. Placental and systemic oxidative stress is considered to be a major underlying mechanism of pathology in preeclampsia ([@B73]). With a view toward melatonin\'s antioxidant properties, it is striking that blood levels and placental synthesis of melatonin decline significantly in women with severe preeclampsia ([@B74]--[@B76]). In a meta-analysis by Dou et al. ([@B77]), these data were corroborated and melatonin levels were found to correlate with the severity of the disease. In terms of a possible beneficial effect of melatonin on placental tissues, Hannan et al. ([@B78]) demonstrated that melatonin *in vitro* upregulated antioxidant response genes in human placental trophoblasts as well as in umbilical vein endothelial cells, albeit only at extremely high (1 mM) levels. A recent pilot clinical study by Hobson et al. ([@B79]) essentially corroborated these *in vitro* findings. These authors reported modest improvements in the duration of pregnancy in a small cohort of women with preeclampsia who had taken 10 mg oral melatonin three times per day from recruitment until delivery. While it seems highly unlikely that these pharmacological concentrations of melatonin reflect *in vivo* circumstances, these results non-etheless open the door for new therapeutic possibilities to improve clinical outcomes for women with preeclampsia.

Melatonin and Parturition {#s5}
=========================

Given its proven role as an endocrine signal of night time duration ([@B7], [@B80]) it was not unexpected to find an influence of melatonin on the timing of parturition. Takayama et al. ([@B81]) showed that female rats whose endogenous melatonin was eliminated by pinealectomy had no disturbances in estrous cyclicity or in their ability to become pregnant, but they failed to deliver their young exclusively during the daytime (early daytime is the normal birthing phase for nocturnal animals, such as rodents). Instead, the rats gave birth randomly across the 24-h light-dark cycle. However, evening administration of melatonin (i.e., at the time when endogenous levels would normally increase) was effective in restoring the normal daytime birth pattern. Importantly, melatonin was ineffectual when given in the morning or continuously. This strongly points to the ***timing*** of birth in the rat being under circadian control, and that melatonin may serve as a key circadian "gating" signal for this event. These data suggest that the clock may play a subtle, but important role in the reproductive process; however, care must be taken when extrapolating rat data to the human as we are largely diurnal (day-time active), whereas the majority of laboratory rodents are nocturnal (night-time active).

The precise mode of action of melatonin in the mammalian uterus, while still not completely understood, is clearly species-specific. Some earlier reports with rodents ([@B82], [@B83]) showed direct *inhibitory* effects of pharmacological doses of melatonin on uterine contractility as well as the presence of melatonin-specific binding sites in the uterus ([@B84]). There are further reports of the inhibitory effects of melatonin on prostaglandin synthesis in various rodent tissues ([@B85], [@B86]). Melatonin has also been shown to modulate calcium signaling in various tissues, including vascular smooth muscle, often via synergistic actions with other receptor-mediated processes ([@B7]). Again, care must also be taken when extrapolating data gathered from nocturnal species, such as the laboratory mouse (C57/Bl6), as these and other strains do not produce endogenous melatonin and their parturition physiology is vastly different from that of the human female.

In contrast to the nocturnal rodent, human labor, and delivery are statistically more common during the night phase ([@B87], [@B88]). In view of its nocturnal secretion pattern and the reported effects of melatonin on uterine contractions in other mammals, it seemed reasonable to explore whether melatonin may act as the "temporal gate" in contributing to the contractions that underlie human parturition.

Data from our laboratory ([@B35], [@B37]) have uncovered a significant positive synergistic action of melatonin and oxytocin (OT) on human myometrial smooth muscle cell contractions *in vitro* in which melatonin results in striking amplification of OT-induced IP~3~ signaling and OT-induced contractions. These findings may explain the high level of nocturnal uterine contractions found in late term human pregnancy that lead to nocturnal labor ([Figure 1](#F1){ref-type="fig"}). More recently, we have also identified a synergistic action of melatonin and OT on myometrial smooth muscle cell induction of the core circadian gene *hBMAL1* ([@B90]). BMAL1 is a transcription factor at the core of the circadian system ([@B91], [@B92]) as it serves to regulate the expression of genes whose promoters contain the E-box motif, which includes the melatonin receptors. OT analogs are important tools in obstetrical practice. Continuous infusion of OT agonists is commonly used to induce labor, while OT antagonists are now used to prolong pregnancy in cases of preterm labor. However, prolonged labor induction by application of continuous OT is only effective when high amounts of the hormone are given \[due to receptor "desensitization"- ([@B93])\]. Unfortunately, continuous OT administration is often accompanied by serious side effects, including fetal distress, uterine rupture, postpartum atony and bleeding. Discovery of a synergism between OT and melatonin signaling ([@B35], [@B37]) could eventually lead to the development of new melatonin + low dose OT medicinal combinations for labor induction without the considerable side-effects of high OT administration. Conversely, studies employing the well-known inhibitory effect of light of circulating melatonin levels have provided corroborating evidence that the nocturnal uterine contractions common to late pregnancy are under melatonin control ([@B94], [@B95]).

![Hypothesized involvement of melatonin with other non-specified uterotonins (e.g., oxytocin, prostaglandins, cytokines) in the establishment of the well-known day night difference in human myometrial contractions during normal late term pregnancy and labor. In this working model the uterine smooth muscle cells are suggested to be in a relaxed state during the daytime because of low levels of melatonin and other unspecified uterotonins (note: the histograms are not meant to be quantitative, but rather to depict relative differences between day and night). High nocturnal uterine contractility is proposed to arise as a synergistic response between uterotonic factors and melatonin, the latter of which is markedly elevated at night. Suppression of nocturnal melatonin levels in late term pregnant women has been demonstrated to significantly reduce uterine contractility ([@B89]).](fendo-11-00085-g0001){#F1}

A strong, parallel upregulation of the melatonin MTNR1B receptor and oxytocin receptor (OTR) protein in the myometrium of ***laboring*** pregnant, as compared to non-laboring pregnant women has also been demonstrated ([@B35]). Parallel trends were noted for *MTNR1A* and *MTNR1B* mRNA expression and for melatonin-binding to these same samples ([@B89]) implying melatonin receptor suppression throughout most of gestation with activation (de-suppression) at the end of pregnancy in preparation for parturition. Although uterine quiescence is thought to be a key function of progesterone during pregnancy \[e.g., ([@B96], [@B97])\], it is unclear whether melatonin receptor activation in the human myometrium at term pregnancy involves changes in progesterone signaling. Interestingly, in preliminary studies of biopsies from women who entered preterm labor, melatonin receptor protein expression was detected in all samples ([@B98]), leading to the fascinating possibility that premature expression of myometrial melatonin receptors may predispose a woman to contractions and preterm labor ([@B99]).

Melatonin in Reproductive Aging {#s6}
===============================

In contrast to early childhood, when high melatonin levels are correlated with low gonadotropin secretion, the presence of low melatonin levels in elderly people appears to be correlated with reproductive aging, i.e., high gonadotropin secretion ([@B100], [@B101]). It is well-established that plasma melatonin levels in elderly individuals are reduced and that the circadian timing of the nocturnal melatonin peak is advanced ([@B102]--[@B105]).

The normal cessation of female reproductive fertility (menopause) is determined by the inability of the ovaries to produce viable follicles and changes in hormonal secretion that leads to failure of menstrual cycles. Thus, clinically, ovarian aging is characterized by a diminished follicular reserve, which correlates with elevated gonadotropin secretion from the anterior pituitary.

An earlier report of mitigation of depression, and improved mood and sleep quality following melatonin administration to perimenopausal and postmenopausal women ([@B106]) could not be confirmed in a study by Amstrup et al. ([@B107]) which found no significant effect on quality of life or sleep quality in 81 postmenopausal women who were given pharmacological melatonin nightly for 1 year. However, these authors did report a non-significant trend toward improved sleep quality in a subgroup of melatonin-treated women who had sleep disturbances at initial baseline. Toffol et al. ([@B108]) showed that postmenopausal women have lower nighttime serum melatonin levels than perimenopausal women; however, they found no correlations between serum melatonin and FSH or estradiol levels, Beck Depression Inventory score, State-Trait Anxiety Inventory score, BNSQ insomnia score, BNSQ sleepiness score, subjective sleep score, climacteric vasomotor score, or quality of life. The apparent discrepancies in the aforementioned studies is probably reconcilable, since in the Bellipanni and Amstrup investigations pharmacological levels of melatonin (3 mg/night for 6--12 months) were administered, while the Toffol study analyzed physiological and psychological correlations with naturally reduced endogenous melatonin levels. More recently however, long term pharmacological melatonin administration was shown to reduce psychosomatic symptoms in postmenopausal women after 12 months of treatment in a double-blind, placebo study ([@B109]). This is consistent with numerous previous studies on the use of pharmacological melatonin in the treatment of sleep disturbances in elderly men and women \[cf. ([@B110])\].

Some studies have proposed a role for melatonin in ovarian aging, given the supportive and pleiotropic effects of melatonin on ovarian activities, including suppression of oxidative stress, protection of mitochondrial integrity, etc ([@B48], [@B111], [@B112]). However, as most of the research to date has been in rodents \[cf. ([@B113], [@B114])\] a clear etiological relationship between declining endogenous melatonin levels and human menopause has not been adequately demonstrated, nor have sufficiently powered clinical trials with melatonin administration to perimenopausal women been reported.

Summary and Future Perspectives {#s7}
===============================

To summarize this short overview of melatonin\'s association with human female reproduction and fertility, melatonin does not have a strong impact on human puberty, although in this regard its contributions as an endocrine output of the circadian clock need further careful study. Its impact on oogenesis and ovulation, while modest, could still be valuable in the development of new treatments for certain forms of female infertility. Along similar lines, pharmacological melatonin, or analogs may ultimately find application in placental therapeutics, e.g., for treating placental inflammation, oxidative stress, and preeclampsia. And finally, melatonin receptors in the human uterine smooth muscles may offer a surprising new target for the management of labor, both term labor and preterm labor.

There is thus far little substantiated information on the potential association between clinical syndromes involving the reproductive system and melatonin deficits (or excess), or melatonin receptor polymorphisms. Luboshitzky et al. ([@B115]) documented increased excretion of the major melatonin metabolite (6-sulfatoxymelatonin) in women with PCOS, although whether this was a consequence of increased or decreased plasma melatonin levels was not apparent. More recently, in a pilot study Tagliaferri et al. ([@B116]) administered pharmacological doses of oral melatonin for 6 months to 40 women with PCOS and reported significant improvements in menstrual cyclicity and normalization of androgen balance. A similar reduction of PCOS-related hirsutism and androgen levels after 12 weeks of melatonin supplementation was also found in a recent investigation by Jamilian et al. ([@B117]). Thus, the therapeutic use of melatonin in women with PCOS-related conditions shows promise, and should be explored further. Interestingly, Song et al. ([@B118]) identified significant gene polymorphism differences in a region of the melatonin type 1 receptor (MTNR1a) between women with polycystic ovarian syndrome (PCOS), but no associated phenotypic differences were seen. Whether other polymorphisms in the human melatonin receptor can be related to other reproductive disorders remains a fascinating though largely uncharted territory.

While research into the potential roles of melatonin in human reproductive physiology continues to expand our intellectual universe after six decades, some common features are apparent. Firstly, melatonin can potentially reach every cell of the body, conveying both circadian information (via plasma melatonin rhythms) and serving as a paracrine modulator of local oxidative state, inflammatory responses, autophagy, etc (e.g., in the ovary and placenta). Some of these actions are likely to be melatonin receptor-dependent, while others may be receptor-independent. In some cases, melatonin may serve as a permissive or synergistic signal, affecting the response of tissues to other molecules (e.g., oxytocin in the uterus). As an ancient molecule that has taken membership in a wide array of cellular processes in all kingdoms of living organisms over the eons of terrestrial biological evolution, melatonin\'s involvement in human reproduction is best described to be subtle, diverse, and essential. For example, from *in utero* fetal programming to the timing of parturition, and from influences on metabolism in key reproductive tissues to modulation of neuroendocrine rhythms, melatonin appears to make contributions to all of these processes.

On a closing note, it is critically important to again make the distinction between physiological effects of melatonin and pharmacological consequences of melatonin administration. This warning is of course not unique for melatonin---consider for example another circadian hormone like cortisol. Similarly, when evaluating target effects of melatonin one must remain attentive to species-specific differences in the responsiveness of any tissue to rhythmic and also non-rhythmic levels of melatonin. Developmental stage, gender differences and genetic variabilities all can affect how a reproductive tissue will respond to melatonin. In this regard, it behooves the melatonin researchers of the future to maintain an open mind and an eye for the unexpected. Clearly, melatonin and/or novel analogs of melatonin will eventually find their place in the armamentarium of reproductive medicine in ways that we probably can\'t even imagine.
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